Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 3
2006 5
2007 4
2008 4
2009 8
2010 13
2011 12
2012 7
2013 9
2014 13
2015 8
2016 8
2017 12
2018 6
2019 13
2020 12
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Results by year
Filters applied: . Clear all
Page 1
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R, Suárez C, González M, Valverde C, Serra E, Mateo J, Raventos C, Maldonado X, Morote J, Carles J. Morales-Barrera R, et al. Among authors: morote j. Cancer Treat Rev. 2020 Jun;86:102000. doi: 10.1016/j.ctrv.2020.102000. Epub 2020 Mar 13. Cancer Treat Rev. 2020. PMID: 32203842 Review.
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Smith MR, et al. Among authors: morote j. Lancet. 2012 Jan 7;379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9. Epub 2011 Nov 15. Lancet. 2012. PMID: 22093187 Free PMC article. Clinical Trial.
Effect of dutasteride on the risk of prostate cancer.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group. Andriole GL, et al. N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127. N Engl J Med. 2010. PMID: 20357281 Free article. Clinical Trial.
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ. Bellmunt J, et al. Among authors: morote j. Cancer Res. 2020 Oct 15;80(20):4476-4486. doi: 10.1158/0008-5472.CAN-20-0977. Epub 2020 Aug 31. Cancer Res. 2020. PMID: 32868381
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Smith MR, et al. Among authors: morote j. J Clin Oncol. 2013 Oct 20;31(30):3800-6. doi: 10.1200/JCO.2012.44.6716. Epub 2013 Sep 16. J Clin Oncol. 2013. PMID: 24043751 Free PMC article. Clinical Trial.
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA. Bancroft EK, et al. Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Eur Urol. 2014. PMID: 24484606 Free PMC article.
[Consensus on castration-resistant prostate cancer management in Spain.].
Alcaraz A, Martínez-Piñeiro L, Rodríguez A, Rubio J, Borque Á, Burgos J, Carballido J, Cózar JM, Crespo I, Esquena S, Gómez-Veiga F, López D, Miñana B, Morote J, Ribal MJ, Solsona E, Suárez JF, Unda M. Alcaraz A, et al. Among authors: morote j. Arch Esp Urol. 2017 Nov;70(9):777-791. Arch Esp Urol. 2017. PMID: 29099380 Spanish.
Reversal Unilateral Ureteral Obstruction: A Mice Experimental Model.
Narváez Barros A, Guiteras R, Sola A, Manonelles A, Morote J, Cruzado JM. Narváez Barros A, et al. Among authors: morote j. Nephron. 2019;142(2):125-134. doi: 10.1159/000497119. Epub 2019 Feb 15. Nephron. 2019. PMID: 30783029
Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer.
Bowden M, Nadal R, Zhou CW, Werner L, Barletta J, Juanpere N, Lloreta J, Hernandez-Llodrà S, Morote J, de Torres I, Orsola A, Cejas P, Long H, Bellmunt J. Bowden M, et al. Among authors: morote j. Sci Rep. 2020 Nov 18;10(1):20135. doi: 10.1038/s41598-020-76904-7. Sci Rep. 2020. PMID: 33208770 Free PMC article.
Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
Morote J, Comas I. Morote J, et al. J Urol. 2021 Feb;205(2):343-345. doi: 10.1097/JU.0000000000001402. Epub 2020 Oct 7. J Urol. 2021. PMID: 33026925 No abstract available.
115 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback